American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al
- PMID: 21769845
- DOI: 10.1002/art.30544
American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al
Comment on
-
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.Arthritis Rheum. 2011 Feb;63(2):337-45. doi: 10.1002/art.30114. Arthritis Rheum. 2011. PMID: 21279990 Clinical Trial.
Similar articles
-
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.Arthritis Rheum. 2011 Feb;63(2):329-30. doi: 10.1002/art.30109. Arthritis Rheum. 2011. PMID: 21279987 No abstract available.
-
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.Arthritis Rheum. 2011 Feb;63(2):337-45. doi: 10.1002/art.30114. Arthritis Rheum. 2011. PMID: 21279990 Clinical Trial.
-
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.N Engl J Med. 2011 Jan 6;364(1):83; author reply 84. doi: 10.1056/NEJMc1012187. N Engl J Med. 2011. PMID: 21208114 No abstract available.
-
Promising new treatments for rheumatoid arthritis - the kinase inhibitors.Bull NYU Hosp Jt Dis. 2011;69(3):233-7. Bull NYU Hosp Jt Dis. 2011. PMID: 22035435 Review.
-
Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.Drugs. 2011 Jun 18;71(9):1121-32. doi: 10.2165/11591480-000000000-00000. Drugs. 2011. PMID: 21711059 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical